Agilent Technologies, Inc.A
NYSE•Healthcare•Diagnostics & Research
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Agilent Technologies, Inc. (A) reported trailing twelve months revenue of $7.23B as of April 2026, a 9.1% increase year-over-year. Quarterly revenue reached $1.83B, reflecting continued top-line momentum.
Agilent Technologies, Inc. generated $1.41B in TTM net income, with quarterly EBITDA of $466.00M. The operating margin expanded from 18.0% to 21.7%, suggesting improving cost efficiency and pricing discipline.
The spread between operating margin (21.7%) and net margin (18.5%) indicates tight cost control with minimal non-operating drag. Net margin has improved from 12.9% a year ago, signaling stronger bottom-line efficiency.
A trades at a P/E of 22.2x (in line with broad market averages) and a P/S of 4.3x. The price-to-book ratio of 4.4x reflects a moderate premium to book value.
The company generated $201.00M in free cash flow over the trailing twelve months, a 87.9% increase year-over-year, indicating cash generation ability. The balance sheet shows $13.06B in total assets with $3.05B in long-term debt against $7.12B in stockholders equity for a debt-to-equity ratio of 0.4, a conservative capital structure. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are stable at ~21.4%, suggesting durable pricing power and cost discipline.
Consistently high ROE averaging 20.3% suggests a durable competitive advantage and efficient capital allocation.
8 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.
TTM revenue has grown consistently (7 of 7 quarters up), with ~11.3% growth over the period. Strong demand durability.
Data-driven red flags and warnings across 21 quarters
Margins are stable or improving at ~21.5% — no sign of cost or pricing stress.
FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.
D/E ratio is 0.4 — conservative capital structure with low financial risk.
Revenue is stable or growing over recent quarters — demand appears durable.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Shares decreased 2.8% — net buybacks are reducing shares outstanding and boosting per-share value.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation